Iconthin Biotech has introduced AlgaeAsta®, a next-generation astaxanthin ingredient developed to meet the escalating purity and safety demands of the global nutraceutical ingredient industry. The launch directly addresses the tightening regulatory frameworks that now require contract manufacturers and brand owners to provide verifiable supply chain data for market entry.

To eliminate the contamination risks and seasonal variations common in traditional open-pond farming, we have shifted production entirely to a controlled, technology-driven environment:

• Closed-Loop Cultivation: AlgaeAsta® is derived from Haematococcus pluvialis grown inside third-generation closed bioreactors, ensuring year-round high concentration and absolute isolation from environmental pollutants.

• Solvent-Free Extraction: We utilize low-temperature Supercritical CO₂ Extraction to isolate the compound. This process eliminates heavy metals and chemical solvent residues while fully preserving the natural molecule’s biological activity.

To simplify integration for commercial product formulators, the new astaxanthin ingredient is available in multiple industry-standard delivery formats. The portfolio includes high-potency oleoresins for softgels, cold-water-dispersible microencapsulated powders for functional foods, nano-emulsions for beverages, and stabilized powders for direct-compression tableting.

This transition to automated, indoor biological manufacturing allows commercial brands to de-risk their raw material sourcing and confidently meet clean-label guidelines across international markets.